Drug Type Personalized antigen vaccine, Therapeutic vaccine, mRNA vaccine |
Synonyms mRNA-based personalized Cancer Vaccine, neoantigen mRNA personalised cancer vaccine, Personalized Cancer Vaccine (PCV) + [6] |
Target- |
Action stimulants |
Mechanism Gene transference(Gene transference), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseSuspendedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 18 Mar 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Austria | 18 Mar 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 24 Oct 2021 | |
Esophageal Carcinoma | Clinical | China | 18 Oct 2019 | |
Non-Small Cell Lung Cancer | Clinical | China | 18 Oct 2019 | |
Adenocarcinoma of large intestine | Clinical | China | 01 May 2018 | |
Advanced Esophageal Squamous Cell Carcinoma | Clinical | China | 01 May 2018 | |
Pancreatic adenocarcinoma | Clinical | China | 01 May 2018 | |
stomach adenocarcinoma | Clinical | China | 01 May 2018 |
Not Applicable | 1 | bvhznpaqzc(cvpvcunxsu) = No grade 3 or higher drug-related adverse events were observed, except for grade 4 thrombocytopenia caused by PD-1 inhibitor treatment. drtngirpdd (rnnhtirtjz ) | Positive | 01 Jan 2024 |